Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness

@article{Rahmani2014TreatmentOR,
  title={Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness},
  author={Mariam Rahmani and Sean Paul and Mathew Nguyen},
  journal={International Journal of Adolescent Medicine and Health},
  year={2014},
  volume={26},
  pages={297 - 301}
}
Abstract This article presents two cases of adolescent males who were admitted to our inpatient psychiatric unit with a psychotic, disorganized presentation. Both males had a genetic vulnerability to mental illness and reported significant substance use. Their symptoms were refractory to treatment and required the use of clozapine. Both patients experienced significant side effects, which limited the maximum daily dose of clozapine. However, they responded to a dose that was much lower than… 

Substance-Induced Psychoses: An Updated Literature Review

The theory that psychosis due to substance abuse is commonly observed in clinical practice is supported, and the propensity to develop psychosis seems to be a function of the severity of use and addiction.

Distinguishing schizophrenia from posttraumatic stress disorder with psychosis

A large genome-wide association study (GWAS) has identified a collection of genes associated with PTSD, and these genes overlap with those identified as increasing the risk of developing schizophrenia.

Psychosis and synthetic cannabinoids

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

The present mini-review aims at deepening both the clinical, psychopathological features of synthetic/chemical NPS-induced psychoses and their therapeutic strategies, according to the different NPS classes implicated, by underlining the main differences with the “classical” psychoses.

A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment

To identify systematically the scientific reports of adverse events associated with the consumption of SCs in the medical literature and poison centre data, this work searched online databases and manually searched reference lists up to December 2014 to identify eligible studies.

Synthetic Cannabinoids

More research is needed to identify which contaminants are typically found in synthetic marijuana and to understand the interactions between different SBCs to better predict adverse health outcomes.

Synthetic Marijuana and Current Treatment: A Literature Review

Treatment for synthetic marijuana toxicity is mainly supportive and psychotic symptoms related to synthetic marijuana use may warrant treatment with high potency antipsychotics like haloperidol and clozapine, making treatment more complex.

References

SHOWING 1-10 OF 33 REFERENCES

Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?

Findings suggest that additional consumption of each substance predicted an earlier age at onset of schizophrenia by approximately 1 additional year.

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

This is the first prospective longitudinal study of adolescent cannabis use as a risk factor for adult schizophreniform disorder, taking into account childhood psychotic symptoms, and the Dunedin multidisciplinary health and development study has a 96% follow up rate at age 26.

Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis

[Can cannabis use increase the risk for schizophrenic psychoses?].

It is concluded that although a causal relationship between cannabis use and schizophrenic psychoses cannot be definitely proven, the available evidence strongly supports its plausibility and indicates that cannabis might cause psychosis especially in individuals with a predisposition for schizophrenia and in adolescents with an early onset of cannabis use.

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.

The Incidence of First-Episode Schizophrenia-Spectrum Psychosis in Adolescents and Young Adults in Montreal: An Estimate from an Administrative Claims Database

Clinical samples obtained from psychiatric services are unlikely to capture all treatment-seeking patients, and epidemiologic surveys have resource-intensive constraints, making this approach challenging for rare forms of psychopathology; therefore, population-based administrative data may be a useful tool for studying the frequency of psychotic disorders.

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison.

The data suggest that clozapine in the present population of newly admitted, acutely psychotic schizophrenic individuals, and in the doses employed, was more effective in overall improvement response, discharge rate, and ameliorating discrete symptoms across the different objective rating scales used than was chlorpromazine (Thorazine) hydrochloride.

Sex difference in age at onset of schizophrenia.

  • A. Loranger
  • Psychology, Medicine
    Archives of general psychiatry
  • 1984
The age at onset of schizophrenia was determined in 100 male and 100 female patients who unequivocally met DSM-III criteria for the illness and the sex difference is not readily apparent, but it could be a valuable clue to some of the causes of schizophrenia.

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study

Self reported cannabis use is associated with an increased risk of subsequently developing schizophrenia, consistent with a causal relation This association is not explained by sociability personality traits, or by use of amphetamines or other drugs Self medication with cannabis is an unlikely explanation for the association observed.